Early study: AI avatar in VR headsets delivers menopause therapy

Roughly 80% of midlife women have hot flashes and night sweats, and a therapy that helps many of them is hard to reach. In a small study presented at The Menopause Society's 2026 annual meeting in San Diego, researchers tested whether a headset and an artificial intelligence could deliver that therapy instead of a clinic.

Cognitive behavioral therapy, or CBT, is a structured talk-based treatment that teaches people to change the thoughts and habits that keep symptoms going. It has proven effective against several menopause symptoms, including hot flashes, insomnia, depression and sexual dysfunction. Hormone therapy remains the gold-standard drug treatment, but only 1.7% of U.S. women were using it in 2023. The main obstacle to CBT is simpler than the science: there are not enough providers within reach of the women who need them.

The team behind the program, MenoZen VR, recruited women aged 45 to 60 who were not on hormone therapy and had bothersome hot flashes, defined as more than 28 episodes a week. They wore a Meta Quest 3S headset and followed modules guided by an AI avatar named Maia. The modules combined CBT with talk therapy, mindfulness and paced breathing exercises, so the avatar walked each participant through the techniques step by step, inside the headset.

The findings come from a qualitative study, which looks at how participants experienced the program rather than measuring symptom change. Lead author Dr. Karisma Suchak of the Cedars-Sinai Center for Virtual Medicine and Health System Transformation says the work "demonstrates early feasibility and acceptability" of the approach. The women involved were highly interested in a personalized, non-drug option built specifically for menopause.

For now, the gain is a proof that the idea holds up with real women, not a treatment available to them. The study's co-author, Dr. Stephanie Faubion, medical director of The Menopause Society, notes that larger studies are needed to determine clinical effectiveness. The sources give no timeline, price or availability for MenoZen VR. If the results hold, the first beneficiaries would be women who have no CBT provider nearby and who cannot or do not want to take hormones, but that step depends on the trials still to come.